New Medium-Term Management Plan Targets for the Fiscal Years Ending March 2021 through March 2025
First written in FY2021. 8 of 10 entries say "Restated". Latest entry: FY2025-H1.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2025-H1RestatedAnnual report
「The interim consolidated accounting period progressed favorably against the initial plan. Against the backdrop of an increase in case numbers and progress on the key initiatives in the medium-term management plan, revenue increased across all product categories.」
For the new plan formulated after the withdrawal of the previous medium-term management plan, the company described favorable progress against the initial plan and progress on its key initiatives. - FY2023DroppedAnnual report
「The medium-term management plan announced in November 2020 was withdrawn because the gap between actual results and the plan had widened as a result of business transformation, including a significant review of the business portfolio. In May 2023, we formulated a new 5-year medium-term management plan covering the fiscal years ending March 2024 through March 2028.」
The medium-term management plan formulated in November 2020 was withdrawn because of the widening gap between actual results and the plan resulting from the review of the business portfolio and other factors. - FY2023-Q3RestatedAnnual report
「There were no material changes during the cumulative third-quarter consolidated period to the management policies, management strategies or other matters established by the Group.」
The company reconfirmed that there had been no material changes to its management policies, management strategies and other matters, including the medium-term management plan formulated in November 2020. - FY2023-Q2RestatedAnnual report
「There were no material changes during the cumulative second-quarter consolidated period to the management policies, management strategies or other matters established by the Group.」
The company reconfirmed that there had been no material changes to its management policies, management strategies and other matters, including the medium-term management plan formulated in November 2020. - FY2023-Q1RestatedAnnual report
「There were no material changes during the cumulative first-quarter consolidated period to the management policies, management strategies or other matters established by the Group.」
The company reconfirmed that there had been no material changes to its management policies, management strategies and other matters, including the medium-term management plan formulated in November 2020. - FY2022RestatedAnnual report
「In November 2020, we formulated a medium-term management plan and set the following performance targets for the 5-year period from the fiscal year ending March 2021 through the fiscal year ending March 2025: an average annual revenue growth rate of 10%, an average annual operating profit growth rate of 15% and an in-house product ratio of at least 50% of revenue. We also established the following 3 key priorities for achieving these performance targets.」
The company reiterated the medium-term management plan's quantitative targets and 3 key priorities of strengthening existing fields, improving profitability and expanding into gastroenterology, and indicated that there had been no material changes. - FY2022-Q3RestatedAnnual report
「There were no material changes during the cumulative third-quarter consolidated period to the management policies, management strategies or other matters established by the Group.」
The company reconfirmed that there had been no material changes during the nine-month period to its management policies, management strategies and other matters, including the new medium-term management plan. - FY2022-Q2RestatedAnnual report
「There were no material changes during the cumulative second-quarter consolidated period to the management policies, management strategies or other matters established by the Group.」
The company reconfirmed that there had been no material changes to its management policies, management strategies and other matters, including the new medium-term management plan formulated in November 2020. - FY2022-Q1RestatedAnnual report
「There were no material changes during the cumulative first-quarter consolidated period to the management policies, management strategies or other matters established by the Group.」
The company stated that there had been no material changes during the first quarter to its management policies, management strategies and other matters, including the new medium-term management plan formulated in November 2020. - FY2021First statedAnnual report
「In response to this business environment and to achieve sustainable growth over the medium to long term, we formulated a new medium-term management plan in November 2020. As performance targets for the fiscal years ending March 2021 through March 2025, we set an average annual revenue growth rate of 10%, an average annual operating profit growth rate of 15% and an in-house product ratio of at least 50%, together with the following 3 key priorities for achieving these targets: 1. Strengthen the foundation of existing fields and achieve stable growth; 2. Improve profitability through cost control and business restructuring; and 3. Expand into the gastroenterology field and prepare for further growth.」
For the new medium-term management plan formulated in November 2020, the company specified for the first time its targets for average annual revenue growth, average annual operating profit growth and the in-house product ratio for the fiscal years ending March 2021 through March 2025, as well as 3 key priorities.